Bayer awards 15-year Xofigo contract to Cardinal Health

摘要

Bayer Healthcare has awarded a 15-year contract to Cardinal Health to manufacture Xofigo (radium Ra 223 dichloride) for the treatment of prostate and hone cancer. As part of the agreement. Cardinal Health will build a 64,000ft~2 facility in Indianapolis, US, dedicated exclusively to the manufacture of the product, which will be distributed primarily in the US and Canada.